We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
+$598M
Cap. Flow %
12.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 78.81%
2 Consumer Discretionary 9.12%
3 Miscellaneous 6.2%
4 Technology 2.01%
5 Communication Services 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
151
Regenxbio
RGNX
$518M
– –
-222,300
Closed -$6.12M
RPRX icon
152
Royalty Pharma
RPRX
$26B
– –
-250,000
Closed -$10.5M
SLDB icon
153
Solid Biosciences
SLDB
$897M
– –
-114,000
Closed -$3.47M
STNE icon
154
StoneCo
STNE
$2.27B
– –
-400,000
Closed -$21.2M
VXRT
155
DELISTED
Vaxart
VXRT
– –
-750,000
Closed -$4.99M
XLI icon
156
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$30.6B
– –
-500,000
Closed -$38.5M
ZNTL icon
157
Zentalis Pharmaceuticals
ZNTL
$298M
– –
-87,400
Closed -$2.86M
EPZM
158
DELISTED
Epizyme, Inc
EPZM
– –
-1,000,000
Closed -$11.9M
PAND
159
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-145,000
Closed -$1.66M
PRVL
160
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-302,750
Closed -$3.08M
3 4 5 6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group deployed $598M of net new capital in Q4 2020, opening 26 new positions and adding to 26 existing holdings. Its largest new stake was Seer Inc: 5,840,911 shares worth $328M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 58% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BioNTech, an estimated $71.8M trimmed.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.